Although reported associations often do not meet the levels of statistical rigor demanded by contemporary genetic studies, a notable exception is the reported association of HLA-DQA1*05 with the development of ADA against infliximab and adalimumab in individuals with IBD (11). This evidence concerns the gene HLA-DQA1 and inflammatory bowel disease.